Statin-induced autoimmune myositis: a proposal of an 'experience-based' diagnostic algorithm from the analysis of 69 patients

Autor: Gagliardo, Carola Maria, Noto, Davide, Giammanco, Antonina, Maltese, Silvia, Vecchio, Luca, Lavatura, Giuseppe, Cacciatore, Valentina, Barbagallo, Carlo Maria, Ganci, Antonina, Nardi, Emilio, Ciaccio, Marcello, Lo Presti, Rosalia, Cefalu, Angelo Baldassare, Averna, Maurizio
Přispěvatelé: Gagliardo, Carola Maria, Noto, Davide, Giammanco, Antonina, Maltese, Silvia, Vecchio, Luca, Lavatura, Giuseppe, Cacciatore, Valentina, Barbagallo, Carlo Maria, Ganci, Antonina, Nardi, Emilio, Ciaccio, Marcello, Lo Presti, Rosalia, Cefalu, Angelo Baldassare, Averna, Maurizio
Rok vydání: 2023
Předmět:
Zdroj: Internal and Emergency Medicine.
ISSN: 1970-9366
1828-0447
Popis: Statin-induced autoimmune myositis (SIAM) represents a rare clinical entity that can be triggered by prolonged statin treatment. Its pathogenetic substrate consists of an autoimmune-mediated mechanism, evidenced by the detection of antibodies directed against the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR Ab), the target enzyme of statin therapies. To facilitate the diagnosis of nuanced SIAM clinical cases, the present study proposes an “experience-based” diagnostic algorithm for SIAM. We have analyzed the clinical data of 69 patients diagnosed with SIAM. Sixty-seven patients have been collected from the 55 available and complete case records regarding SIAM in the literature; the other 2 patients represent our direct clinical experience and their case records have been detailed. From the analysis of the clinical features of 69 patients, we have constructed the diagnostic algorithm, which starts from the recognition of suggestive symptoms of SIAM. Further steps provide for CK values dosage, musculoskeletal MR, EMG/ENG of upper-lower limbs and, Anti-HMGCR Ab testing and, where possible, the muscle biopsy. A global evaluation of the collected clinical features may suggest a more severe disease in female patients. Atorvastatin proved to be the most used hypolipidemic therapy.
Databáze: OpenAIRE
Externí odkaz: